Comparative efficacy of preprandial or postprandial humalog® mix75/25™ versus glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus

Matthias Herz,Bin Sun,Zvonko Milicevic,Pamella Erickson,Jozsef Fövènyi, Marek Grzywa,Terezie Pelikanova

Clinical Therapeutics（2002）

引用 37|浏览1

暂无评分

摘要

Background: Humalog® Mix75/25™ (Mix75/25) is a novel premixed insulin containing 75% neutral protamine lispro (an intermediate-acting insulin) and 25% insulin lispro.

查看译文

关键词

type 2 diabetes mellitus,postprandial insulin lispro,insulin pens,elderly patients,oral agent failure

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要